Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: bill small who wrote (3981)	4/3/1998 12:30:00 PM
From: Peter Singleton	Read Replies (1) \| Respond to of 6136

AGPH is down 1 11/16 to 36 7/16. Anyone have an opinion? Is this a single large seller? A judgment on the past quarter? Noise level in the stock price?

To: bill small who wrote (3981)	4/3/1998 1:14:00 PM
From: StockDoc	Read Replies (2) \| Respond to of 6136

Hi there, just joining. The potential market for AG3340, if it works better or safer than its competitor compounds, is gigantic. Far bigger than any AIDS drug or all of them, combined. My estimate is over 10 B/y. The competition is in the metalloproteinase and angiogenesis inhibitor fields. The ideal drug is oral, inexpensive, non-toxic and curative. I think AG3340 is oral and might not be very expensive. However, I'm aware of only one entirely safe and curative drug but it is an injectable (disadvantage) peptide (expensive) combination, still in animal models. StockDoc